NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that second-quarter revenues were essentially flat compared to a year ago.

For the three months ended June 30, revenues inched up .5 percent year over year to $1.91 billion, up from $1.90 billion, missing Wall Street estimates of $1.94 billion.

Clinical testing revenues during the quarter inched up .7 percent, Quest said.

SG&A spending was down 5 percent to $440.8 million from $462.8 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.